SYS6055
Phase 2Small molecule
SYS6055 is one of 44 small molecule programs targeting Lymphoma. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
370 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
SYS6055
BBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
Phase 2
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
Not yet recruiting·BBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd·Phase 1/2·NCT07476066·374 enrolled
Relapsed/Refractory B-cell Malignancies1 trial
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07493174·86 enrolled
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma1 trial
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Not yet recruiting·BBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd·Preclinical·NCT07905261·384 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYS6055. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details